Future research should explore the molecular heterogeneity of IgM MM, particularly the biological implications of t(11;14) in this context, and whether targeted strategies such as BCL-2 inhibition (e.g., venetoclax) offer therapeutic advantages. This evidence concerns the gene CD40LG and Miyoshi myopathy.